Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, March 8, 2023
[ Wed, Mar 08th 2023
] - WOPRAI
Tue, March 7, 2023
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
[ Tue, Mar 07th 2023
] - WOPRAI
Corinne Jenkins Maintained (ACRS) at Strong Buy with Decreased Target to $21 on, Mar 7th, 2023
Corinne Jenkins of Goldman Sachs, Maintained "Aclaris Therapeutics, Inc." (ACRS) at Strong Buy with Decreased Target from $25 to $21 on, Mar 7th, 2023.
Corinne has made no other calls on ACRS in the last 4 months.
There are 2 other peers that have a rating on ACRS. Out of the 2 peers that are also analyzing ACRS, 0 agree with Corinne's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Corinne
- Louise Chen of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $38 on, Tuesday, February 7th, 2023
- Alex Thompson of "Stifel" Initiated at Strong Buy and Held Target at $29 on, Wednesday, December 14th, 2022
